Oncotarget

Research Papers:

Peripheral CD4+ naïve/memory ratio is an independent predictor of survival in non-small cell lung cancer

Peng Yang, Junhong Ma, Xin Yang and Wei Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:83650-83659. https://doi.org/10.18632/oncotarget.19330

Metrics: PDF 1447 views  |   HTML 2149 views  |   ?  


Abstract

Peng Yang1, Junhong Ma1, Xin Yang2 and Wei Li1

1Department of Thoracic Surgery, Linyi People’s Hospital, Linyi 276000, China

2The Statistics Research and Consulting Laboratory, Culverhouse College of Commerce and Business Administration, The University of Alabama, Tuscaloosa, AL 35487, USA

Correspondence to:

Wei Li, email: [email protected]

Keywords: non-small cell lung cancer, T cells, CD45RA, CD45RO, survival

Received: May 17, 2017     Accepted: June 19, 2017     Published: July 18, 2017

ABSTRACT

Background: To investigate the clinical significance of naïve T cells, memory T cells, CD45RA+CD45RO+ T cells, and naïve/memory ratio in non-small cell lung cancer (NSCLC) patients.

Methods: Pretreatment peripheral blood samples from 76 NSCLC patients and 28 age- and sex-matched healthy volunteers were collected and tested for immune cells by flow cytometry. We compared the expression of these immune cells between patients and healthy controls and evaluated their predictive roles for survival in NSCLC by cox proportional hazards model.

Results: Decreased naïve CD4+ T cells, naïve CD8+ T cells, CD4+ naïve/memory ratios and CD4+CD45RA+CD45RO+ T cells, and increased memory CD4+ T cells, were observed in 76 NSCLC patients compared to healthy volunteers. Univariate analysis revealed that elevated CD4+ naïve/memory ratio correlated with prolonged progression-free survival (P=0.013). Multivariate analysis confirmed its predictive role with a hazard ratio of 0.35 (95% confidence interval, 0.19-0.75, P=0.012).

Conclusions:Peripheral CD4+ naïve/memory ratio can be used as a predictive biomarker in NSCLC patients and used to optimize personalized treatment strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19330